Common side effects include: Gastrointestinal issues: Nausea, vomiting, constipation, and abdominal pain Injection site reactions: Redness, swelling, and pain Systemic issues: Fatigue, indigestion, heartburn, belching, and hair loss More severe side effects include: Thyroid problems: Medullary thyroid cancer and pancreatitis with severe, persistent abdominal pain Gallbladder problems with symptoms such as upper abdominal pain, fever, jaundice, or clay-colored stools Increased risk of hypoglycemia with symptoms such as dizziness, sweating, confusion, and shakiness Severe vomiting that leads to dehydration and kidney problems Mental health concerns such as depression and suicidal thoughts Vision changes from rapid changes in blood glucose levels Some patients should not use Zepbound, such as those who have or are at risk for medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
The results suggest that tirzepatide treatment is associated with statistically significant reductions in albuminuria compared to placebo/insulin at all three doses of the drug used in the RCTs we assessed (except with the 5 mg dose when compared to placebo)
Hispanic adults are at greater risk for developing diabetes and diabetes-related complications and unfortunately also experience more barriers to accessing health care (e.g., work, caregiving, transportation)
Results VRK2-deficient PC cells are vulnerable to GSH inhibition To investigate the impact of VRK2 on metabolic reprogramming, we treated VRK2-wild-type (VRK2-WT) and VRK2-knockout (VRK2-KO) CFPAC-1 cell lines with 281 metabolism compounds (Supplementary Table1)
